China chip stocks rally on self-reliance bets, Nvidia scrutiny
NEW YORK - Lucid (NASDAQ:LCID) Diagnostics Inc. (NASDAQ:LUCD), a medical diagnostics company specializing in cancer prevention, has regained its compliance with the Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company, a subsidiary of PAVmed Inc . (NASDAQ:PAVM), achieved this by maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days, as of February 21, 2025. According to InvestingPro data, the stock has shown remarkable momentum with a 70% surge over the past six months, though it recently experienced a 13% pullback in the past week.
The Nasdaq Capital Market had previously notified Lucid Diagnostics of its non-compliance due to the company’s stock failing to meet the required minimum closing bid price of $1.00 for 30 consecutive business days. Meeting the 10-day requirement has allowed Lucid to rectify its standing with the exchange.
Lucid Diagnostics focuses on patients with gastroesophageal reflux disease (GERD), who are at an increased risk of developing esophageal precancer and cancer. The company’s EsoGuard® Esophageal DNA Test, used alongside the EsoCheck® Esophageal Cell Collection Device, provides a noninvasive office procedure designed for the early detection of esophageal precancer in at-risk patients. These tools are the first and only commercially available options aimed at preventing cancer through early detection.
The company’s common stock will continue to be traded on the Nasdaq Capital Market under the ticker symbol "LUCD." This announcement is based on a press release statement from Lucid Diagnostics. For deeper insights into LUCD’s valuation metrics, growth prospects, and comprehensive financial analysis, investors can access the detailed Pro Research Report available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Lucid Diagnostics has entered into a partnership with LEAA Health, marking its entry into the concierge medicine market. This collaboration allows LEAA Health members to access Lucid’s EsoGuard Esophageal DNA Test, which is designed for early detection of esophageal precancer. The partnership is part of Lucid’s strategy to expand the market presence of EsoGuard and aligns with the growing trend towards prevention-focused healthcare. Meanwhile, PAVmed, the parent company of Lucid Diagnostics, announced it has regained compliance with Nasdaq’s stockholders’ equity listing requirements. This was achieved by increasing its stockholders’ equity to over $2.5 million through strategic financial actions, including the deconsolidation of Lucid Diagnostics and restructuring of convertible debt. The Nasdaq Listing Qualifications Department confirmed PAVmed’s compliance, ensuring its securities will continue to be listed on the Nasdaq Capital Market. PAVmed will be subject to a one-year monitoring period to maintain this compliance. Both companies have issued standard cautionary statements about forward-looking risks and uncertainties in the medical technology industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.